Monitor for any strategic shifts in Innovative Medicine under Cavanaugh's leadership, but no near-term trading catalyst from this filing.
JNJ drugs
JNJ drug pipeline →- ▲ DARZALEX 4/10 Approved (multiple FDA-approved multiple-myeloma indications); additional label-expansion Phase 3 studies completed.
- ◆ IMAAVY 4/10 Approved (first indication); NDA under FDA review for wAIHA
- ● SPRAVATO 4/10 Approved
- ▲ TREMFYA 4/10 Approved (marketed); BLA 761061 with multiple supplemental approvals; further Phase 3 label-expansion studies ongoing/co
- ▲ CARVYKTI 3/10 Approved (marketed); ongoing Phase 2/3 studies
- 12 more · All JNJ drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 4 $254.93entry
- T+1 · 3mo ago +1.04%α +1.24% · $257.59
- T+5 · 3mo ago +1.91%α +2.01% · $259.80
- T+20 · 3mo ago +6.38%α +7.62% · $271.19
- T+60 · 20d ago +5.41%α +5.63% · $268.73
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Johnson & Johnson announced the retirement of Jennifer Taubert, EVP and Worldwide Chairman of Innovative Medicine, effective September 1, 2026, with Tom Cavanaugh appointed as her successor. This is a routine leadership transition at a mega-cap pharmaceutical company with a named internal replacement, carrying no material financial impact.
Key Facts
- Jennifer Taubert to retire as EVP, Worldwide Chairman, Innovative Medicine effective September 1, 2026.
- Tom Cavanaugh appointed as successor, effective September 1, 2026, and will join the Executive Committee.
- Taubert had a 21-year tenure at J&J; under her leadership, Innovative Medicine grew to more than $60 billion in annual revenue.
- Cavanaugh has nearly 30 years of biopharma experience, including 9 years at J&J and prior roles at Celgene.
Financial Impact
No financial impact disclosed; routine executive succession at a $617.8B market cap company.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000200406-26-000167 |
| Document: pressrelease08042026.htm | 0000200406-26-000167 |
| Document: 0000200406-26-000167-index-headers.html | 0000200406-26-000167 |
| Document: 0000200406-26-000167-index.html | 0000200406-26-000167 |
| Document: 0000200406-26-000167.txt | 0000200406-26-000167 |
Track record
21 reports on JNJ
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +13.24% at T+60 after the May 13, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Mixed 3/10 Entry $289.75 Now $285.75 −1.38% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $283.52 Now $285.75 +0.79% settles Feb 10
- Oct 13, 20264w ago 8-K Mixed 6/10 Entry $248.61 Now $285.75 +14.94% settles Jan 8
- Sep 30, 20266w ago Court Ruling Bullish 6/10 Entry $258.66 Now $285.75 +10.47% settles Dec 28
- Sep 24, 20267w ago Court Ruling Neutral 3/10 Entry $271.22 Now $285.75 +5.36% settles Dec 21
- Sep 9, 20269w ago Court Ruling Neutral 1/10 Entry $266.35 Now $285.75 +7.28% settles Dec 4
- Aug 18, 202612w ago Insider Cluster Neutral 2/10 Entry $273.41 to $283.52 Now $285.75 +4.51% ▲ +3.70% +5.25% vs SPY
- Aug 14, 202613w ago Insider Cluster Neutral 2/10 Entry $262.37 to $280.78 Now $285.75 +8.91% ▲ +7.02% +9.96% vs SPY
- Aug 7, 202614w ago Insider Cluster Neutral 3/10 Entry $261.81 to $266.17 Now $285.75 +9.14% ▲ +1.67% +4.08% vs SPY
- Aug 7, 202614w ago Court Ruling Bearish 4/10 Entry $261.81 to $266.17 Now $285.75 −9.14% ▼ −1.67% −4.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers